Upcoming events

    • April 26, 2018
    • 5:30 PM - 9:00 PM
    • Embassy Suites, 550 Winter Street, Waltham, MA

    Intraoperative and Post-Op Intravesical Treatment of    Non-Muscle Invasive Bladder Cancer

    Featured Speaker:  Mark A. Preston, MD

    Assistant Professor of Surgery

    Harvard Medical School

    Urologic Surgeon

    Brigham & Women's Hospital


    The treatment of non-muscle invasive bladder cancer (NMIBC) has been based on intravesical therapy for decades. The mainstay of treatment has been BCG based therapy for decades, however, the paradigm is changing. Recent evidence has shown that intravesical placement of chemotherapy at the time of primary resection has markedly decreased recurrence rates. However, the agent of choice is debatable, and evidence is suggesting a new line of treatment maybe in order. It is the hope of this program to elucidate the issues and to enhance the audience's knowledge of the current controversies and allow for a more informed decision making on the part of both physician and patient.

    The literature is suggesting that intravesical gemcitabene may be a better agent to use at the time of resection for NMIBC. This is a shift from mitomycin based treatment. This program will help to identify the issues and best practices at this time.

Past events

November 15, 2017 MAPU Fall Meeting - Physician Burnout in Urology
April 26, 2017 MAPU 2017 Annual Meeting
December 08, 2016 2016 MACRA Meeting
November 15, 2016 2016 MAPU Fall Program
April 27, 2016 2016 Annual Meeting
November 04, 2015 Fall Conference


American Medical Systems 
Astellas Pharmaceuticals, Inc.
Astellas Pharmaceuticals, Inc.
Boston Scientific
Genomic Health
Janssen Biotech
Karl Storz
Know Error
Master Pharm Compounding Pharmacy
Metamark Genetics, Inc.
New England Pathology Associates
Quantum Pathology
Richard Wolf Medical Instruments Corporation
Stratadx Pathology Services
United Medical Systems

Wild Apricot development by Webbright